Replimune Group (NASDAQ:REPL) Shares Up 10.9% – Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL) shot up 10.9% on Wednesday . The stock traded as high as $8.98 and last traded at $9.3730. 323,089 shares changed hands during trading, a decline of 67% from the average session volume of 977,758 shares. The stock had previously closed at $8.45.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Monday, October 20th. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a report on Monday, October 20th. Finally, HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Replimune Group Trading Up 6.2%

The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The firm has a market cap of $704.16 million, a price-to-earnings ratio of -2.59 and a beta of 0.72. The firm’s fifty day moving average is $9.56 and its 200-day moving average is $7.61.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 5,208 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $47,392.80. Following the transaction, the insider directly owned 123,088 shares of the company’s stock, valued at $1,120,100.80. This represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. The trade was a 2.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,625 shares of company stock valued at $257,607 over the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares in the last quarter. BNP Paribas Financial Markets raised its position in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Replimune Group in the 2nd quarter valued at $69,000. GSA Capital Partners LLP bought a new position in Replimune Group during the 3rd quarter valued at $81,000. Finally, Griffin Asset Management Inc. purchased a new position in Replimune Group during the 3rd quarter worth $82,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.